🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our latest feature is out now! 🎉 Learn more about how CAR-T is changing the treatment landscape for hematologic malignancies, with insight from Kai Rejeski, Tania Jain, Michael Jain, and Joshua Brody, MD. 📚 buff.ly/IU7K4ul

Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation Out on Lancet Oncology sciencedirect.com/science/articl… A recent workshop organized by the National Cancer Institute, Immuno-Oncology

SITC’s Lymphoma CPG update includes the latest guidance in the rapidly changing treatment landscape, addressing several new IO approvals for ICIs, ADCs, CAR T cell therapies, and bispecific antibodies. Learn more: ow.ly/4Zft50VpHwk #SITCGuidelines #Lymphoma #Immunotherapy

Congratulations to Brian Brown, PhD, elected to AIMBE College of Fellows for his pioneering contributions to gene therapy and functional genomics. bit.ly/4hU8zXW Brown Lab Icahn School of Medicine at Mount Sinai

Which steroid* is right for CRS?! *Hint - it rhymes with dexamethasone. #lymphoma #immunotherapy #bispecifics Emmanuel Bachy haematologica.org/article/view/1…

Quick and insightful Commentary by Professor Carlo-Stella on our recent Blood paper on combining #lymphoma #immunotherapy with SOC Mount Sinai Health System sciencedirect.com/science/articl… sciencedirect.com/science/articl…

Elegant genetic #cancer #immunotherapy from Yizhou Dong The Tisch Cancer Institute Lipschultz Precision Immunology Institute mobilizing #dendritic cells to teach T cells to recognize and kill tumors! Icahn School of Medicine at Mount Sinai bit.ly/4jwfsA1

Beautiful description by Gvantsa Pantsulaia Gvantsa Pantsulaia of how to optimize high-throughput CD4/CD8 T cells P-flow experiments to deeply investigate immunological signaling in developing new #cancer #immunotherapy Lipschultz Precision Immunology Institute The Tisch Cancer Institute sciencedirect.com/science/articl…

Crystal-clear illustration by Matt Lin, PhD Daniel Charytonowicz how to measure T-cell (and CAR-T) BYSTANDER tumor killing to prevent antigen escape after #cancer #immunotherapy Lipschultz Precision Immunology Institute The Tisch Cancer Institute authors.elsevier.com/a/1kwL6,25QIwR…

#RichterSyndrome still a huge unmet need in #CLL and #Lymphoma, here's a coherent consensus statement by world-expert Adam Kittai Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute and colleagues - ashpublications.org/blood/article/…

Cool, quick summary of by Moah Sohn on how to #CRISPR edit T-cells to understand and improve them for #cancer #immunotherapy Lipschultz Precision Immunology Institute The Tisch Cancer Institute authors.elsevier.com/a/1kxli,25QIwR…

🚨 LIVE at #ASCO25! 🧬 Dive into the evolving role of bispecific antibodies in treating R/R FL & DLBCL. Get expert insights from Joshua Brody, MD & Tycel Phillips on data, patient selection & practical use. 👉 ms.spr.ly/6016SKkVq

Do #lymphoma and other #tumors have antigen(-) cells that can evade #CART and #BiTE #immunotherapies... and how can we characterize them? Dr. Ivan Odak shows how: authors.elsevier.com/a/1kwL6,25QIwR… Lipschultz Precision Immunology Institute The Tisch Cancer Institute

Amazing remissions using #CART #lymphoma #immunotherapy from Tim Fenske Nirav Shah and team!!

9th Annual Live Medical Crossfire®: Heme Malignancies July 26, 2025 Conrad New York Downtown, NY, NY Chairs: Barbara Pro, Saad Usmani, Amer Zeidan Registration: gotoper.com/MXHFOF *Exclusive Discount* FREE registration when using my last name as code during checkout "BRODY"

9th Annual Live Medical Crossfire®: Heme Malignancies July 26, 2025 Conrad New York Downtown, NY, NY Chairs: Barbara Pro, Saad Usmani, Amer Zeidan Registration: gotoper.com/MXHFOF *Exclusive Discount* FREE registration when using my last name as code during checkout "BRODY"

🚨 HAPPENING AT #ASCO25 🔬 Explore how bispecific antibodies are transforming care in R/R FL & DLBCL! Gain insights into trial data 📊 , selection criteria, and real-world strategies to personalize treatment. 👉 ms.spr.ly/6015Sdnzl Experts: Joshua Brody, MD + Tycel Phillips

On May 31, we'll explore a variety of tumor types related to bladder and prostate cancers, as well as lymphomas. Register for any of the events. Urothelial Bladder: ow.ly/Qi4T50VTY9E Non Hodgkins Lymphoma: ow.ly/4bVf50VTY9I Prostate: ow.ly/C32S50VTY9K

.Joshua Brody, MD, Brown Lab, Theodora Anagnostou, MD and colleagues analyze cancer vaccine trials and different vaccine approaches, and discuss how the next generation of cancer vaccines can help improve patient outcomes and quality of life. authors.elsevier.com/a/1lHcZV-4XSfX Icahn School of Medicine at Mount Sinai

#18ICML | The Lymphoma Hub was pleased to speak with Joshua Brody, MD Icahn School of Medicine at Mount Sinai. We asked about the clinical significance of the long-term results from the EPCORE NHL-2 trial, which evaluated epcoritamab plus R-CHOP for previously untreated high-risk DLBCL.